Aria,
I'm not very good at predicting price action. And I know nothing about the value of the science. So keep those two things in mind.
My cost average basis on ZIOP is slightly under $3.50/share, so obviously the risk-reward ratio is different than it was when I first bought. The pluses are that the science seems solid, from knowledgeable people that I have spoken to. And the management team seems first-rate. And the principal investigators are guys like Larry Norton (at Sloan-Kettering) and Larry Einhorn (at Indiana), both considered "thought-leaders" in their respective areas.
But is it a "buy" here with an almost $300 million market cap? I'm not so sure. McBio and rkrw know more than I do and are probably better judges than I am. There might be better places in oncology to invest in at the moment (e.g., ARRY, CLDX, IMMU)). And, if the sarcoma results for ARIA are not good and the stock tanks, then that might be a real buying opportunity in ARIA.
In any case, let's hope for good news from MRK/ARIA in sarcoma.
Bladerunner
News 
Market Data 
Discover 
